TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract SessionsGlobeNewsWire • Monday
TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewsWire • 03/28/24
TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical ProgramsGlobeNewsWire • 03/27/24
TFF Pharmaceuticals Announces Oral Presentation of Interim Data from the Phase 2 Study of Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 MeetingGlobeNewsWire • 03/25/24
TFF Pharmaceuticals Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesGlobeNewsWire • 03/22/24
TFF Pharmaceuticals Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesGlobeNewsWire • 03/20/24
TFF Pharmaceuticals to Participate in the 36th Annual Roth Conference – March 17-19, 2024GlobeNewsWire • 03/14/24
TFF Pharmaceuticals to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder (TFF VORI) for the Treatment of Invasive Pulmonary Aspergillosis at the 11th Advances Against Aspergillosis & Mucormycosis ConferenceGlobeNewsWire • 01/24/24
TFF Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for Presentation at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 MeetingGlobeNewsWire • 01/09/24
TFF Pharmaceuticals Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TACGlobeNewsWire • 12/19/23
TFF Pharmaceuticals to Host Webcast and Conference to Review Initial Data from the Ongoing Phase 2 Trials of TFF VORI and TFF TACGlobeNewsWire • 12/18/23
TFF Pharmaceuticals to Participate in the 2023 Benchmark Discovery One-on-One Investor Conference – December 7, 2023GlobeNewsWire • 11/27/23
TFF Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/14/23
TFF Pharmaceuticals Announces Publication of Data Demonstrating Feasibility of Intranasal Delivery of Monoclonal Antibodies with Thin Film FreezingGlobeNewsWire • 11/08/23
TFF Pharmaceuticals to Hold Third Quarter 2023 Financial and Business Results Conference Call on November 14, 2023GlobeNewsWire • 11/07/23
TFF Pharmaceuticals Congratulates our Scientific Advisory Board Member, Drew Weissman, M.D., Ph.D., for Receiving the Nobel Prize in Physiology or Medicine for his Pioneering Work Enabling the Development of mRNA COVID-19 VaccinesGlobeNewsWire • 10/02/23
TFF Pharmaceuticals to Participate in the H.C. Wainwright 25th Annual Global Investment Conference – September 11-13, 2023GlobeNewsWire • 08/23/23
TFF Pharmaceuticals Announces Closing of $5.7 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment OptionGlobeNewsWire • 08/17/23